Can a lower dose of rivaroxaban be safer for kidney patients on dialysis?
NCT ID NCT05410275
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This study is testing three different low doses of the blood thinner rivaroxaban in 10 adults on chronic hemodialysis. The goal is to see how the drug behaves in the body and how much it thins the blood, to find a dose that might lower bleeding risks. Participants will take each dose for three days, and researchers will measure drug levels and clotting activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEMODIALYSIS PATIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
01-Arauco
RECRUITINGTours, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
02-TOURS
RECRUITINGTours, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rivaroxaban
What this could lead to
If successful, this could help determine a safer dose of rivaroxaban for dialysis patients who need blood thinners, potentially reducing bleeding risks.
What could go wrong
This is a very small early-phase study with only 10 participants, so results may not apply to all patients. The drug may still cause bleeding or not work as expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.